Anthem Biosciences reported a 22.6% year-on-year decline in consolidated revenue from operations to ₹4,182 Mn for the quarter ended June 30, 2026. The company attributed the decline to timing shifts in deliveries to key customers, noting that underlying demand remains strong with a higher concentration of scheduled deliveries expected in the latter half of the year. Consolidated profit after tax (PAT) decreased by 11.7% to ₹1,199 Mn, while EBITDA margins expanded by 153 basis points to 39.6% despite the revenue drop.

Consolidated Financial Performance

The CRDMO segment led revenue generation with ₹3,408 Mn, while the Specialty Ingredients segment contributed ₹774 Mn. On a year-on-year basis, CRDMO revenue fell 24.7% and Specialty Ingredients revenue declined 11.5%. Total consolidated expenses for the quarter stood at ₹2,985.25 Mn. The company reported a net cash position of ₹17,197 Mn as of June 30, 2026, compared to ₹7,848 Mn in the prior year.

Standalone Financial Performance

Standalone revenue from operations fell to ₹3.84B compared to ₹5.38B in the same period last year. Standalone net profit declined to ₹1.02B versus ₹1.48B in the prior year period. The standalone EBITDA for the quarter came in at ₹1.31B, with an EBITDA margin of 34.08%, contracting from 36.32% in the same quarter last year. The Statutory Auditors, K. P. Rao & Co., issued a Limited Review Report expressing an unmodified opinion on the results.

Corporate Actions and Outlook

During the quarter, the company allotted 1,670,909 fully paid-up equity shares of ₹2 each under the ESOP Scheme 2024. The paid-up equity share capital post-allotment increased to ₹1,126.77 Mn. Management emphasized that disciplined focus on cost efficiencies, yield optimisation, and employee productivity reinforced the industry-leading margin profile, positioning the company to sustain performance through the year.

Anthem Biosciences has confirmed that its promoter group did not pledge or encumber any shares during the financial year ended March 31, 2026. This disclosure ensures that the shareholding structure remains free of liens or charges, which is critical for maintaining shareholder confidence and regulatory compliance. The declaration was submitted to BSE and NSE on April 10, 2026, by Ishaan Bhardwaj on behalf of the promoter and promoter group.

The filing was made pursuant to Regulation 31(4) and 31(5) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. These regulations require promoters to disclose any encumbrance over shares held directly or indirectly. The confirmation from the promoter group indicates that no such financial arrangements were established involving the company's equity during the specified period.

Promoter Group Details

The disclosure identified the members of the promoter group, including Ishaan Bhardwaj and seven other individuals. The list was provided as Annexure A to the regulatory filing. The group consists of both Indian residents and foreign nationals, with specific details regarding their Permanent Account Numbers (PAN) where applicable.

The company requested that the exchanges place this information on record. A copy of the declaration was also forwarded to the Audit Committee of Anthem Biosciences Limited for its information and records.